Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2025-06-24 00:00:00 ET · period of report 2025-06-20 · accession 0001415889-25-018116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-06-24 | 2025-06-20 | ELVN | Lyssikatos Joseph P | CSO | S - Sale | $21.40 | -12.5K | 965.2K | -1% | -$267.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-20 | S | D | 12,500 | $21.40 | 965,188 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $21.1228 to $22.0249. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. |